Valeant Pharma (VRX) Tops Q4 EPS by 5c; Guides In-Line

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. ARM
3. FIS
4. BROS
5. QCOM
6. EXPE
7. FSLY
8. CPAY
9. FICO
10. PAYC

Go back to Valeant Pharma (VRX) Tops Q4 EPS by 5c; Guides In-Line

Valeant Reports Fourth Quarter And Full Year 2016 Financial Results And Provides 2017 Guidance

February 28, 2017 7:00 AM EST

LAVAL, Quebec, Feb. 28, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company" or "We") today announced fourth quarter and full year 2016 financial results.

"Today, we announced financial results that delivered on expectations and demonstrated our commitment to creating the new Valeant," said Joseph C. Papa, Chairman and Chief Executive Officer. "Over the past few months, our teams worked to stabilize and strengthen our core businesses, resolve legacy issues, improve operational processes, launch new products,... More